DrugPatentWatch Database Preview
Ucb Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?
UCB INC has forty approved drugs.
There are eighteen US patents protecting UCB INC drugs.
There are three hundred and forty-six patent family members on UCB INC drugs in fifty countries and forty-three supplementary protection certificates in fourteen countries.
Summary for Ucb Inc
| International Patents: | 346 |
| US Patents: | 18 |
| Tradenames: | 27 |
| Ingredients: | 22 |
| NDAs: | 40 |
| Drug Master File Entries: | 1 |
| Patent Litigation for Ucb Inc: | See patent lawsuits for Ucb Inc |
Drugs and US Patents for Ucb Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | PARCOPA | carbidopa; levodopa | TABLET, ORALLY DISINTEGRATING;ORAL | 076699-002 | Aug 27, 2004 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ucb Inc | BRIVIACT | brivaracetam | TABLET;ORAL | 205836-002 | May 12, 2016 | RX | Yes | No | Start Trial | Start Trial | |||||
| Ucb Inc | GASTROCROM | cromolyn sodium | CAPSULE;ORAL | 019188-001 | Dec 22, 1989 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ucb Inc | BRIVIACT | brivaracetam | SOLUTION;INTRAVENOUS | 205837-001 | May 12, 2016 | RX | Yes | Yes | 6,911,461 | Start Trial | Y | Y | Start Trial | ||
| Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-002 | Oct 28, 2008 | RX | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ucb Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-003 | Jan 19, 2005 | 6,024,981 | Start Trial |
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | 4,344,949 | Start Trial |
| Ucb Inc | NIRAVAM | alprazolam | TABLET, ORALLY DISINTEGRATING;ORAL | 021726-002 | Jan 19, 2005 | 6,024,981 | Start Trial |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | 4,743,450 | Start Trial |
| Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-003 | Oct 28, 2008 | 5,654,301 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UCB INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2012-10-29 |
| ➤ Subscribe | Extended-release Tablets | 1000 mg | ➤ Subscribe | 2011-01-07 |
| ➤ Subscribe | Tablets | 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg | ➤ Subscribe | 2004-01-15 |
| ➤ Subscribe | Extended-release Transdermal Film | 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr | ➤ Subscribe | 2013-11-26 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2012-10-29 |
| ➤ Subscribe | Injection | 10 mg/mL, 20 mL | ➤ Subscribe | 2016-06-30 |
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2005-12-27 |
| ➤ Subscribe | Tablets | 1000 mg | ➤ Subscribe | 2007-01-24 |
International Patents for Ucb Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 324485 | Start Trial |
| Germany | 60119397 | Start Trial |
| Japan | 5753645 | Start Trial |
| Australia | 2001252144 | Start Trial |
| Russian Federation | 2292336 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ucb Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1110543 | SPC/GB08/005 | United Kingdom | Start Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| 1110543 | 08C0004 | France | Start Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| 0503785 | CA 2011 00026 | Denmark | Start Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 1452524 | CA 2016 00013 | Denmark | Start Trial | PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118 |
| 1429780 | 13C0012 | France | Start Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
